Lasmiditan effective for acute migraine, with or without concomitant preventive medication

  • Loo LS & al.
  • J Headache Pain
  • 24/07/2019

  • Kelli Whitlock Burton
  • Clinical Essentials
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

Takeaway

  • Patients using concomitant migraine preventive medications reported significant improvement in acute migraine pain 2 hours after taking lasmiditan compared with placebo.

Why this matters

  • Results come from a subanalysis of 2 randomized trials of lasmiditan, which demonstrated efficacy in reducing pain and symptoms from acute migraine but did not examine efficacy in patients who took preventive medications and those who did not.

Study design

  • Post hoc analysis of 2 randomized, double-blind, placebo-controlled phase 3 studies (n= 3981; episodic migraine with/without aura).
  • Treatment groups received placebo or oral lasmiditan (50, 100, or 200 mg).
  • Funding: Eli Lilly and Company, Indianapolis, Indiana, USA.

Key results

  • 17.5% of the patients received migraine preventive treatments.
  • Of all preventives used, most common were antiepileptics (35%), beta blockers (32.3%), and antidepressants (25.5%).
  • All doses of lasmiditan (vs placebo) significantly increased (P<.05 the percentage of patients with freedom from pain and most bothersome symptom at hours.>
  • Groups receiving/not receiving preventive medications showed no significant differences for pain- and MBS-free outcomes at 2 hours (all interaction, P>.1).

Limitations

  • Lasmiditan (50 mg) was included in only 1 trial.

Coauthored with Chitra Ravi, MPharm